Accession Number:

AD1035508

Title:

Biomaterials for Improved Wound Healing

Descriptive Note:

Technical Report,15 Sep 2009,14 Sep 2013

Corporate Author:

The Geneva Foundation Lakewood United States

Personal Author(s):

Report Date:

2013-10-01

Pagination or Media Count:

29.0

Abstract:

With current combat operations there is high incidence of infection and a continuing need for innovative approaches to wound healing and tissue regeneration. The early and aggressive administration of antimicrobial treatment starting with intervention on the battlefield has resulted in improved patient outcomes and is considered standard of care. Unfortunately, while previous research in the development of effective antimicrobial agents, none has the ideal formulation for the treatment of battlefield wounds. Therefore, effective agents that are more appropriate for use on combat wounds must be developed. In order to address this problem, we will develop new treatment protocols, drug delivery systems and tissue engineered biologics to reduce wound-related infections and accelerate wound healing using a military relevant infected burndebridement model. This will be accomplished by developing a novel biodegradable gel based antimicrobial dressing for battlefield administration to minimize post injury complications and infection. This gel will provide local delivery of antibacterial to the site of injury, prevent colonization of bacteria and reduce dependence on high doses of systemic antibiotics. The result will be a sterilized prepackaged biodegradable gel that will allow optimal handling and placement that inhibits infection and promotes tissue revascularization. Second, for those soldiers who have been evacuated from the battlefield, we will use the gel in combination with autologous stem cells. This tissue engineering based strategy will provide the surgically debrided wound a matrix for neovascularization and tissue regeneration to limit the loss of life and limb.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE